The recent case report by Thompson and colleagues on late-onset neutropenia with clozapine raises a few questions (1) . The authors do not define mild neutropenia and incorrectly call an absolute neutrophil count (ANC) of 1.86 x 109/L mild neutropenia. The most accepted definition of mild neutropenia is an ANC of 1.0 to 1.5 x 109/L (2) . Further, the authors do not elaborate on the role of valproic acid in the presentation of clozapine-induced neutropenia. Valproic acid is independently associated with neutropenia (3). In addition, a case report describes a patient on a combination of sodium valproate and clozapine who developed a potentially serious drop in white cell and neutrophil counts that reversed on discontinuation of valproate (4). On the basis of this report, the investigators recommended that consideration should be given to stopping sodium valproate before the thresholds are reached for the discontinuation of clozapine. Clozapine-induced neutropenia is much more common than agranulocytosis (cumulative incidence of 2.7% and 0.73%, respectively) (5) , which means that a substantial proportion of patients experiencing neutropenia with clozapine treatment do not progress to agranulocytosis. Transient or benign neutropenia not progressing to agranulocytosis has been described in the literature, and some patients with mild neutropenia have been shown to do well on continued treatment with clozapine (6) . It has been suggested that drug interaction may be responsible for neutropenia in clozapine-treated patients and that clozapine need not necessarily be discontinued (7) . Given that clozapine is administered to treatment-resistant patients, balancing potential side effects like agranulocytosis and clinical deterioration assumes greater significance, especially in patients developing mild neutropenia while taking other medications with a potential to cause neutropenia. Thus it would have been interesting to see whether this patient's neutropenia would have resolved had the valproic acid been discontinued. Nevertheless, this report highlights the need for future research to explore alternate options when treating clozapine-induced mild neutropenia while continuing clozapine and also to devise means to differentiate benign neutropenia from neutropenia progressing to agranulocytosis.
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Reply: Late-Onset Neutropenia With Clozapine
Dear Editor:
We appreciate the opportunity to respond to Dr Duggal and Dr Singh, and we welcome their comments. We agree with their observation that an accepted strict definition of mild neutropenia is an absolute neutrophil count of 1.0 to 1.5 x 109/L. We used the term mild neutropenia to reflect the neutrophil count being designated within the "amber" range as defined by the Clozaril Patient Management System (1). This designation prompts the need for biweekly blood draws.
We are aware that the role of concomitant valproic acid needs to be considered, given the evidence that it can cause direct bone marrow suppression producing blood dyscrasias including neutropenia (2) .
In this case, there was no evidence of neutropenia with valproic acid prior to the institution of clozapine. Further, cessation of the clozapine alone resulted in a gradual resolution of the neutropenia, which was sustained, to our knowledge, for at least 2 years and despite the addition of risperidone and the patient's remaining on valproic acid.
With hindsight, it might have been worthwhile to discontinue the valproic acid prior to being forced to cease the clozapine. However, the history of a grand mal seizure would argue against ceasing the valproic acid in the first instance.
Thankfully, in this particular scenario, the patient's symptoms responded satisfactorily to risperidone, with the added benefit of less onerous hematological surveillance.
